SecBot SecBot
8-K ·Filed Jul 2, 2026

LFCR

LIFECORE BIOMEDICAL, INC. \DE\
BEARISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001005286-26-000026
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

Lifecore must secure additional financing (equity, debt, or strategic transaction) and lender consent before the December 28, 2026 redemption deadline. Monitor for an equity offering that would dilute common shareholders, or asset sale announcements. The 1% monthly penalty for non-payment adds urgency and could pressure the stock.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.09
T+0 close · Jul 2, 2026 · via day close
Latest settled
+28.09%
T+60 · $6.52
Vs SPY
+24.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $5.09entry
  2. T+1 · 4mo ago −0.79%α −1.66% · $5.05
  3. T+5 · 4mo ago −6.68%α −7.61% · $4.75
  4. T+20 · 4mo ago −14.34%α −13.93% · $4.36
  5. T+60 · 7w ago +28.09%α +24.53% · $6.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical disclosed that holders of all 49,263 outstanding Series A Redeemable Convertible Preferred shares have submitted redemption notices, requiring approximately $52.1 million in cash by December 28, 2026. The company's current liquidity of $38.1 million ($20.8M cash + $17.3M revolver) falls short of this obligation, and lender consent is needed to proceed. Management is evaluating strategic alternatives including debt/equity financing or asset sales to fund the redemption, creating near-term uncertainty and dilution risk for common shareholders.

Key Facts

  • Holders of all 49,263 shares of Series A Redeemable Convertible Preferred Stock submitted redemption notices between June 29-30, 2026
  • Redemption price is $1,000 per share plus accrued dividends; total required amount ~$52.1 million due December 28, 2026
  • Accrued and unpaid dividends of $0.9 million as of June 30, 2026; total liquidation value ~$50.2 million
  • The company had $38.1 million in total liquidity as of March 31, 2026 ($20.8M cash + $17.3M revolver availability)
  • Lender consent is required under existing credit agreements which prohibit such payments without approval
  • Failure to redeem fully by Dec 28, 2026 triggers a 1% per month interest penalty on the unpaid balance

Financial Impact

$52.1M redemption obligation within 6 months exceeds current $38.1M liquidity by ~$14M, necessitating additional capital raising or lender consent

liquiditydebtdilutioncash

Risk Factors

  • Equity dilution if common stock is issued to raise redemption funds
  • Default on credit agreements if lender consent is not obtained
  • Accrual of 1% monthly penalty interest on unpaid redemption amount
  • Potential going-concern concerns if financing cannot be secured

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001005286-26-000026
Document: 0001005286-26-000026-index-headers.html0001005286-26-000026
Document: 0001005286-26-000026-index.html0001005286-26-000026
Document: 0001005286-26-000026.txt0001005286-26-000026

Track record

20 reports on LFCR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026